Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Qiagen's Singapore play

Qiagen N.V. announced plans last week to establish a Singaporean joint venture that will combine its expertise in the field of assay development with BioOne Capital Pte. Ltd.'s inside access to local research

Read the full 336 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE